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ABSTRACT 
Colorectal cancer (CRC) is the third leading cause of cancer deaths with an 
estimated 57,000 deaths per year in the United States. Evidence for a role of 
estrogens in colon cancer is accumulating, although the mechanism through which 
this is mediated is not clear. Epidemiological studies suggest that post-menopausal 
hormone replacement therapy (HRT) reduces CRC incidence. There is also 
evidence to suggest populations that consume soy and soy foods have reduced 
colon cancer risk. Soy contains phytoestrogens, such as the isoflavone genistein, 
that are similar to endogenous estrogens. Several studies have suggested 
isoflavones may have potential anticarcinogenic effects. In previous work, our group 
found a reduced colon tumor incidence in carcinogen-treated mice fed diets 
containing estrone (E1). Moreover, several epidemiological studies indicate a 40-
50% reduction in the risk of developing colorectal cancer with chronic use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin. It is suggested that 
NSAIDs providE~ anticancer activity by inhibiting both isoforms of the cyclooxygenase 
(COX) enzyme: COX-1 and COX-2. Increased COX-2 activity is an early event in 
CRC. With emerging evidence indicating suppression of COX by estrogens we 
hypothesized that dietary genistein or estrone (E1) would reduce aberrant crypt foci 
(ACF), purported preneoplastic markers of colon carcinogenesis, and 
cyclooxygenase-2 (COX-2) protein levels. Ovariectomized female mice were fed 
diets containing casein (Casein), soy protein without isoflavones (Soy-IF), soy 
protein with genistein (Soy+Gen) or soy protein with estrone (Soy+E1) from 3 weeks 
of age. Starting at 4 weeks of age, all animals were administered weekly injections 
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of azoxymethane (AOM) 10 mg/kg of body weight for 6 weeks, and then terminated 
6 weeks after the last dose of AOM. Colons sections stained with methylene blue 
were visualized under a light microscope forACF, and COX-2 protein levels were 
analyzed by Western Immunoblot. A significant effect of diet on COX-2 protein 
levels but not A►CF was observed. COX-2 protein levels were lower in mice fed 
Soy+E1 and Soy+Gen compared with mice fed Casein or Soy-IF. Thus, we 
conclude that soy protein with genistein and soy protein with estrone downregulated 
COX-2 levels ire mouse colon suggesting a potential role in reducing colon cancer 
risk. 
1 
CHAPTER 1 
LITERATURE REVIEW 
Overview of colorectal cancer 
Cancer remains one of the most common malignancies in Western countries, 
including the United States and other developed countries (1). Cancer accounts for 
approximately ;?3% of total deaths, ranking second only to heart disease in the 
United States (1). Colon cancer is the third most commonly diagnosed cancer 
among men and women next only to lung and prostate/breast cancer (1, 2). The 
incidence of colorectal cancer (CRC) is about 1 million (9.4%) world wide with no 
significant differences between men and women (1, 2). In the United States, the 
estimated deaths due to CRC were 56,290 with 28,540 and 27,750 among men and 
women, respectively, in 2005 (2). 
Although, there is little overall gender difference in the risk of colon-cancer, 
the age-specific colon cancer gender ratios vary considerably. Males tend to have a 
higher risk than females of CRC until 35 years of age after which the mortality and 
incidence rates among women increases remarkably resulting in little overall gender 
difference in colon cancer risk (3). The observation by McMichael and Potter (3) in 
age-specific colon cancer ratios between sexes especially below 35 years and 
between 35-54 years led them to suggest a role for female sex hormones in the 
etiology of colon cancer. Further, the transient decline in colon cancer mortality 
rates in women between ages 35-44 during the early 1970's against an overall 
increasing trend in other years made them to suggest a correlation to the use of oral 
contraceptives by women a decade earlier (3). 
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There is at least 25-fold variation in the occurrence of CRC world wide with 
the highest incidence being in North America, followed by Australia and other 
developed countries (1-3). The vast geographical variation in the incidence could be 
attributed to the differences in environmental exposures including diet (1-3). 
Epidemiological studies pertaining to the migrant Asian population to Western 
countries and their increase in incidence rates of CRC even in the first generation 
indicate the rolE~ of environment, particularly that of diet in this disease (1, 2, 4). 
Furthermore, a large discrepancy in the incidence and mortality rates of colon 
cancer between ethnic groups in the United States has also been reported. African 
Americans have the highest incidence rates, whereas Hispanics, Asians/Pacific 
Islanders, and American Indians/Alaskan Natives have the lowest, with the incidence 
in Whites falling in the middle (2, 5). The contribution of diet to these differences has 
not been well defined. 
Environment and diet in the etiology of cancer 
Many environmental factors contribute to CRC incidence rates. Some of 
these environmental factors include carcinogens (whether identified or not) such as 
man-made chemicals or naturally occurring carcinogens, viral infections, nutritional 
deficiencies or excesses, reproductive activities, physical activity, radiation exposure 
that can be controlled wholly or partly by lifestyle changes. An important role of 
nurture/environment in the etiology of colon cancer was first proposed by Doll and 
Peto (6). Some of the major avoidable causes of cancer include tobacco, alcohol, 
diet, food additives, reproductive and sexual behavior, occupation, pollution, 
medicines and i~nedicinal procedures, infection, geophysical factors, and industrial 
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products (7). For many years there has been strong but indirect evidence that many 
of the cancers could be avoided by lifestyle changes (6). After an extensive review of 
literature the American Institute of Cancer Research and World Cancer Research 
Fund concluded that cancer is principally caused by environmental factors which 
include tobacco, diet and factors related to diet, including body mass index and 
physical activity, and occupational exposures (7). Consumption patterns of meat, fat 
(specifically animal fat), and fiber have been strongly correlated with the incidence of 
colon cancer (7-10). 
Dietary factors contribute to perhaps half of the leading causes of death of 
Americans including cardiovascular disease, cancer and diabetes (1). There are 
inconsistencies linking diet with different types of cancer despite the fact that 
numerous studies suggest a significant role of diet (11-13). Plant-derived foods, 
often referred to as phytochemicals, may provide protection at several stages of the 
multifactorial grid multistage complex nature of colon cancer (14). Examples of 
components that have been recognized to have a protective effect against cancer in 
model systems include essential nutrients such as calcium, zinc, folate, vitamin C, D, 
and E, non-essential bioactive food components such as carotenoids, n-3 fatty 
acids, conjugated linoleic acid and isoflavones (8, 15). Modifying one or more of the 
cancer processes such as carcinogen metabolism, hormonal balance, cell signaling, 
cell-cycle control, apoptosis or angiogenesis may be the mode of action of these 
compounds (14). 
Legumes and beans are among the significant sources of protein in the 
traditional diets of many regions of the world (16). It is hard to imagine Asian 
cuisines without soy beans, lentils, black beans, chick peas, and pinto beans while 
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Western cuisines are based on animal protein and the associated animal fats. In 
addition to being a good source of dietary fiber (soluble and insoluble), these foods 
have been associated with decreased CRC risk (12, 17). Plant-derived foods are 
also good source of phytochemicals. 
With the general consensus that diets high in red meat and the associated 
saturated fat arse strongly correlated with increased colon cancer risk, substituting 
soy protein for red meat may decrease CRC (4, 16, 18). Soy is a common dietary 
component in Asian diets. Soy protein is considered a high quality protein for 
humans and is equivalent to milk protein based on the FDA protein digestibility 
corrected amino acid score method (19). With the versatility of soy to be processed 
in various ways along with the recent approval by the FDA for a health claim on soy 
based foods to reduce cardiovascular disease risk; the consumption of soy has 
increased substantially in the United States (20). 
Soy protein 
Soy foodls and soybean components have received considerable attention for 
their potential to reduce cancer risk. Numerous studies have focused on soy intake 
and risk of breast cancer (21-23). The relationship between soy intake and other 
cancers, including CRC also gained attention due to the several anti-carcinogenic 
bioactive compounds found in soy (16). Some of which include isoflavones, 
phytosterols, fatty acids, fiber, and protease inhibitor (trypsin inhibitor) (18). These 
biologically active components may contribute individually or synergistically to the 
health benefits associated with soy. 
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Figure 1.1. Structure of isoflavones (phytoestrogens) and the endogenous 
estrogens (estradiol and estrone) 
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Isoflavones (IF) such as genistein and daidzein, are found in high 
concentration in soy. Due to their structural similarity to estradiol (Figure.1.1) and/or 
their biological activity these compounds are often referred to as phytoestrogens (16, 
24). These plant-derived compounds have inherent estrogenic activity (25) or may 
be converted to estrogenic compounds by bacteria in the intestines (26, 27). Most 
often the muco~al or the bacterial R-glucosidases cleave the glucose moiety of the 
glucosides which are then absorbed and glucoronidated. Further metabolism of 
daidzin results in equol, an active metabolite that has more potent estrogenic activity 
than the parent compound. Genistein is metabolized to p-ethylphenol and 4-
hydroxypheny-2-propionic acid (27). Isoflavones also possess other potentially 
important biological attributes in addition to their ability to bind to the estrogen 
receptor. Some of the cancer-related properties associated with genistein include 
its anti-oxidant activity, anti-promotional effect (28), inhibition of tyrosine kinase (29), 
aromatase (30) DNA topoisomerase (31), inhibition of cell cycle progression and 
growth (32), and inhibition of angiogenesis in endothelial cells (28, 29, 32, 33). 
Results from studies on the effect of soy and soy isoflavones in CRC using 
animal models are inconsistent. Table 1.1 summarizes the conflicting results 
obtained with soy or the isoflavones in Aberrant crypt foci (ACF) formation and colon 
tumorigenesis. Thiagarajan et al (34) reported 50% reduction in ACF in male rats 
fed soy concentrate with genistein (167 mg/kg of diet) that were administered 2 AOM 
injections at 15 mg/kg of body weight. However, this report was contradicted by Gee 
et al (35) who used dimethylhydrazine (DMH) to induce ACF in male Wistar rats. 
They reported a 3-fold increase in ACF in rats fed casein-based genistein diet. 
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There are several differences between these studies that may provide explanation 
for these opposing results. Some of which include the use of casein based pure 
genistein diet by Gee et al (35) against the soy concentrate based genistein diet by 
Thiagarajan et al (34), use of different carcinogens to induce ACF such as DMH vs. 
AOM, the duration of the study (i.e., 6 weeks after carcinogen treatment vs 12 week 
after AOM) and dietary treatment before, during and after carcinogen treatment are 
some of the possible confounders. However, most of the long term studies on tumor 
incidence have indicated protective or no effect of soy or soy isoflavones. 
Previously we observed that oral administration of estrone with soy protein 
decreased tumor incidence, but not burden (tumor weight) or multiplicity in wild type 
and ERaKO mice (36). Though the effect of genistein was not statistically 
significant, this study showed that genistein reduced tumorigenesis in wild type as 
well as ERaKO mice. Similar results were reported in ovariectomized APCmin mice 
(31). Administration of estradiol/genistein reduced the tumor incidence in these 
mice. Also, a 20% reduction in tumor incidence in male rats fed soy protein isolate 
with 276 mg/kg of body weight compared to casein control was reported by Hakkak 
et al (37). However, Rao et al reported enhancement of noninvasive 
adenocarcinoma in rats fed casein based diets with genistein compared to controls. 
They also observed no effect of genistein on colon adenocarcinoma incidence or on 
the multiplicity of invasive adenocarcinoma (38). The contradictory result could be 
due to the use of casein based diets over soy protein based diets used by us. 
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Human epidemiological studies also provide contradictory evidence as to the 
role of soy in CRC risk. A 12-month intervention trial reported a decrease in colon 
epithelial cell proliferation with soy supplementation compared to casein group (39). 
A meta-analyses of epidemiological studies associating soy intake with CRC risk 
indicated a reduction in mean overall risk of colon cancer (40) (16, 18). In a study 
conducted of the US population with 50% Caucasians as subjects, an inverse 
association between high intake of carotenoid vegetables, garlic, or tofu (fermented 
soybean product) with polyps was reported. However, a 12-month randomized 
intervention study on men and women recently diagnosed with adenomatous 
polyposis reported no decrease in colon epithelial cell proliferation when 
supplemented with soy protein powder containing different amounts of isoflavones 
(41). The study participants were supplemented with 58 g of soy protein containing 
83 mg of isoflavones/day (45.6 mg of genistein, 31.7 mg of daidzein and 5.5 mg of 
glycitenin in aglycone units) or ethanol extracted soy protein powder containing 3 mg 
of total isoflavones. They reported no decrease in colorectal epithelial cell 
proliferation with soy protein supplementation but an increase in cell proliferation 
measures in thE~ sigmoid colon. Moreover, Nagata et al (42) showed a significant 
positive correlation between CRC mortality rates and soy food intake after correcting 
for age, smoking, alcohol and animal fat intake in the Japanese population (42). 
With these conflicting results on the effect of soy on CRC, some showing a 
protective effect while others a negative effect more studies on the role of soy in 
CRC are needed 
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Role of estrogen in CRC 
The importance of estrogen in homeostatic regulation of many cellular and 
biochemical events is well established with the various pathophysiologic changes 
that occur with estrogen deficiency (24). Fraumeni et al (43) reported a high 
incidence of CRC among nuns along with high incidence of other hormone-
associated cancers including breast, uterus and ovary. Although, there is little 
overall gender difference in the risk of colon cancer, there is a variation in the age-
specific colon cancer gender ratio especially in the age groups of 35-54 and above 
54 among men and women. Men had higher risk below 35 years of age while the 
risk was higher in females between 35-54 years of age. After 54 years of age the 
male risk again becomes higher (3). McMichael and Potter et al (3) observed a 
transient decline in female colon cancer risk ratio among 35-54 and 55-74 year olds 
in the 1960's and early 1970's. Peak age-specific fertility and exposure to high-dose 
of oral contraceptives during 1960's were suggested to be possible reason for this 
transient decline in women indicating the direct influence of endogenous/exogenous 
estrogen in colon cancer. Several case-controlled studies and cohort-studies 
examining the associations between reproductive events, menstrual factors, 
exogenous hormones and CRC stratified by age at diagnosis, tumor site, family 
history and other potential risk factors also indicated the role of female sex 
hormones on colon cancer (44, 45). In ameta-analysis of 18 epidemiologic studies 
on postmenopausal HRT and CRC Grodstein et al (46) found a 20% reduction in the 
risk of colon cancer and a 19% decrease in the risk of rectal cancer for 
postmenopausal women on hormone therapy compared to women who never used 
hormones (46). The role of estrogen in decreasing CRC was further reiterated with 
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the outcome of the Women's Health Initiative trial. Two parallel randomized 
controlled clinical trials, one with conjugated equine estrogen (CEE) alone and the 
other with CEE in combination with progestin (medroxyprogesterone acetate (MPA)) 
were undertaken to determine the effect of HRT in reducing cardio- vascular risks 
(47). The arm with CEE with progestin was halted in July, 2002 as the health risks 
of this treatment exceeded its benefits (47, 48). The primary adverse outcome 
included invasive breast cancer along with coronary heart disease. However, the 
incidences of GRC in women using CEE + progestin were lower than nonusers. 
Thus, suggesting a protective effect of HRT in CRC (47, 49). However, women in 
the HRT group who developed CRC had a greater number of positive lymph nodes 
suggesting a more advanced invasive type of CRC with HRT. The reason for this is 
not known, and demonstrates the need for more study of the role of estrogen in 
CRC. 
Estrogen receptors 
Estrogen mediates temporal and tissue-specific actions via estrogen 
receptors (ER) a and ~3. The ER receptors are members of the nuclear receptor 
superFamily of transcription factors that include thyroid receptor, vitamin D receptor, 
retinoic acid receptor, and other steroid receptors such as the glucocorticoid, 
mineralocorticoid, androgen and progesterone receptor. ERa was the first estrogen 
receptor that was isolated from MCF-7 human breast cancer cells followed by the 
ER~3 from rat prostate using degenerate PCR primers (50). ERa and ERR are 
localized in the breast, brain, cardiovascular system, urogenital tract and bone (50-
12 
52). ERa is the main subtype in the liver, while ERR is the main ER in the colon 
(50). 
Ligands such as estrogen (estradiol) binding modulate the transcription of 
target genes. Activity of the transcription factors is regulated by a variety of factors, 
including phosphorylation, corregulators, and the effector pathway in addition to 
ligand binding. The end result of the target genes is to modulate physiological 
processes, such as reproductive organ development and function, bone density as 
well as the growth and development of breast and endometrial cancer. These 
biological effects are mediated via communication between many proteins and 
signaling pathways (50). The susceptibility of a tissue to estrogen-induced 
carcinogenesis might be determined by the ratio of ERa:ER~3 (53). Phytoestrogens 
such as genistein have a greater affinity for ER~3 compared to ERa by 20-fold, but 
activates transcription through both receptors (50). 
Location of Estrogen receptors in colon 
ERa and ER~3 may also localize to distinct cellular subtypes within each tissue 
(50). Waliszewski et al (54) reported the location of ER to be in the stromal cells 
rather than in the colon epithelial cells and in situ hybridization studies also indicated 
the presence of ER in stromal cells above the muscularis mucosa (55). However, 
Xie et al (56) reported the presence of ER throughout the colon mucosa by 
immunohistochemistry. Controversy remains over the location of these receptors in 
the stroma rather than in colon epithelial cells and their role in colon cancer. But, a 
consistent finding is that normal human colon expressed more ER~3 than ERa mRNA 
and expression of ERR is low or selectively lost in human colon tumor cells. (53, 57) 
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Estrogen synthesis in colonic epithelium 
Estrogen can be synthesized locally with tissue specificity. The precursor for 
estrogen is cholesterol which is converted to pregnenolone and 17-
hydroxypregnenolone. Dehydroepiandrosterone (DHEA) derived from 17-
hydroxypregneu~olone is converted to androstenedione or androstenediol. 
Conversion of androstenedione into testosterone is governed by the enzyme 17R-
hydroxysteroid dehydrogenase (17RHSD). The enzyme complex aromatase, 
cytochrome P450 a~om transforms these androgens into estrogens (58). Conversion 
of estradiol (E2) to estrone (E1) or the reverse facilitated by 17R-HSD depends on its 
oxidative or reductive activity (58-60). There are at least nine different isoforms of 
17~3HSD whose activity differs with in tissues accounting for the differences in the 
varying concentrations of these steroids in different cells (61). It is speculated that 
the peripheral synthesis of estrogens may play a role in the non-receptor mediated 
effect of estrogen in the pathophysiology of cell growth (59, 61). The role of estrone 
and estradiol in colon cancer cells is not well defined. Oduwole et al (61) reported 
that 17(3-HSD type 2 (estradiol to estrone) was the dominant form in human colon 
and was downr~egulated in colorectal tumors with no expression of the 173-HSD type 
1 enzyme (estrone to estradiol). However, they also reported that females with CRC 
that had higher 173-HSD 2 mRNA expression had a poor survival rate thus 
suggesting a low expression of the 17R-HSD type 2 as an independent marker of 
good prognosis in females with distal colorectal cancer (62). This was contradicted 
by English et al (59) who reported conversion of estradiol to estrone as protective 
against colon cancer and loss of estrogen inactivation (i.e., conversion of active 
estradiol to estrone and 17-HSD type 2 enzyme) results in colon tumors. These 
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results suggest a reciprocal role of active and inactive estrogens (estradiol and 
estrone) in the etiology of colon cancer 
Both endogenous and exogenous sex hormones have been associated with 
cancer etiology. High levels of biologically active androgens or estrogens are 
associated withu increased risks of prostate cancer in men and ovarian and breast 
cancer in women (63-65). Despite the positive association of endogenous and 
exogenous estrogens with these cancers, plant estrogens are inversely associated 
with cancer (66, 67). The association of phytoestrogens with decreased cancer 
incidence implies a lack of estrogenicity or estrogen antagonism or differential 
cellular mechanisms. The growth effect of estradiol (1 and 10nM) to genistein and 
tamoxifen was compared on cellular proliferation in human colon cancer cell lines 
(HT-29, Co1o320, Lovo and SW480 cells) and MCF-7 cells (67). Even at higher 
concentrations (100 and 500nM) the colon cancer cells were not responsive to 
estradiol while growth was stimulated in MCF-7 cells. However, at 10~M 
concentrations of genistein at which growth is stimulated in ERa positive human 
breast cancer MCF-7 cells there was a slight inhibition in growth of HT-29, Co1o320 
and Lovo colon cancer cells. Also, they reported the presence of ERR in these cells 
with no ERa. Different biological effects of the phytoestrogens and endogenous 
estrogens as will as the differences in ratio of ERa and ER~3 can be accounted for 
the differential effects of these compounds tissue specifically. 
Types of cancer 
Inherited or acquired mutations in the adenomatous polyposis coli (APC) gene or 
mismatch repair genes (MMR) have been associated with colon carcinogenesis (68). 
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Hereditary forms of colon cancer include familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colorectal cancer (HNPCC) (4, 69). The progression from 
adenomatous polyps characterized by benign neoplasms arising from glandular-type 
cells occurs via a multistage carcinogenesis pathway (68, 70). FAP is an autosomal, 
dominant inherited syndrome that affects about 1 in 7000 individuals and is caused 
by an inherited mutation in the adenomatous polyposis coli (APC) gene (70). The 
mutations can arise at different sites within APC, that invariably lead to stop codons 
and thus a truncated APC protein (4, 68). Hypermethylation of APC can also cause 
truncation of the APC protein (71). Genetic polymorphisms with a nontruncating 
APC have also been described (4). Although, FAP patients have more adenomas 
they do not necessarily turn into carcinomas. The common and early somatic event 
in polyps and cancer include mutations at the APC locus which could be due to a 
first germline hit or a somatic event. Other mutations in the transforming growth 
factor R receptor, k-ras oncogene and p53 tumor suppressor genes have also been 
described (72, 73). The predisposition to multiple primary cancers such as 
endometrial, ovarian, gastric, and urinary tract without intestinal polyposis along with 
microsatellite instability (MIN) is the hallmark of HNPCC. The silencing of APC or 
MMR genes leads to hereditary forms of cancer. HNPCC, another inherited 
autosomal dominant syndrome accounts for about 2% of CRC cases where the 
mismatch repair (MMR) genes are mutated but patients do not necessarily have 
polyps or adenomas. 
Sporadic colorectal cancer: CRC arising from nongenetic origins are called 
sporadic cancer. The lifetime risk of CRC is around 5% with about 50°/o of the 
Western population developing adenoma by the age of 70 (2). The etiology is a 
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cumulative mutational activation of oncogenes coupled with inactivation of tumor-
suppressor genes, and genetic alteration in a preferred sequence leading to 
malignant tumors (68, 74). In most cases the initiation of sporadic cancers occurs 
due to environmental factors, therefore this type of cancer has the greatest potential 
for dietary prevention. 
CRC results from the progressive accumulation of genetic and epigenetic 
alterations that transform the normal colonic epithelium to colon adenocarcinoma. 
The basic teneis concerning the pathogenesis of sporadic CRC include changes at 
the molecular and morphologic levels leading to progression, the clonal growth 
advantage of the transformed cells arising from genetic and epigenetic alterations, 
and loss of genomic instability (73). Mutations in the APC gene that leads to 
truncation of the APC protein is often the initial event in tumorigenesis which results 
due to loss of heterozygosity (loss of both alleles of APC). Genetic and epigenetic 
changes of the normal epithelial cells trigger a sequence of events leading to 
adenoma-carcinoma formation. Figure 1.2. depicts the sequence of events leading 
to carcinoma and eventually to metastasis. Genetic mutations such as k-ras, 
SMAD4 and other alterations in addition to APC and R-catenin mutations that result 
in dysregulatior~ of the wnt signaling pathway are also involved in tumorigenesis 
(73). Cyclooxgygenase-2 (COX) protein levels as well as activity are also elevated 
in the early stages of colorectal carcinogenesis. 
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Figure 1.2. Genetic model of colorectal carcinogenesis 
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Animal models in colorectal cancer 
The present understanding of the genetic, molecular and histopathological 
events that are perceived to occur during colon carcinogenesis has been possible 
due to the use cif animal models. These models are also extremely valuable in 
developing strategies for chemoprevention due to their similarity in mimicking the 
neoplastic processes that occur in humans. The models that have been widely used 
in deducing the events and mechanisms associated with colon carcinogenesis 
include chemical carcinogen-induced animal models such as azoxymethane (AOM) 
or dimethylhydrazine (DMH), transgenic models, and immuno-incompetent mice 
xenografted with cancer cells (75). The multiple intestinal neoplasia (Min) mice, with 
a mutation in the APC gene are also widely used. Variations in this model include 
the APC°716 knock out mice introduced by Oshima et al (76). Although, this model is 
similar to FAP in humans, multiple neoplasia develop in the small intestine of these 
mice in contrast to adenomas detected exclusively in the colon and duodenum of 
humans (77). Although, the APCmin mice have 40-60% APC mutations, 
adenocarcinomas or p53 inactivation are rarely observed. The occurrence of the 
polyps in the small intestine rather than the colon is a major drawback in these 
mutant models in addition to the cost in generating these mice (78). 
Aromatic amines, derivates and analogues of cycacin such as 
methylazoxymethanol (MAM), 1,2,-dimethylhydrazine (DMH) and Azoxymethane 
(AOM), as well as direct-acting carcinogens such as methynitrosourea (MNU), and 
heterocyclic amines are some of the chemicals used to induce colon tumors. AOM 
is widely used key many investigators to induce tumors in mice. CYP2E1 belonging 
to the CYP-450 enzyme family metabolizes AOM to methyazoxymethanol (MAM) by 
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hydroxylation of methyl groups. Oxidation of MAM to methylazoxyformaldehyde 
yields methyldiazoniumion which forms DNA adducts (79). The morphology, 
histochemical properties and the biological behavior of these AOM-induced colon 
carcinomas are similar to human colon carcinomas. Other similarities with AOM-
induced colon carcinomas to humans which make it a good chemically induced 
colon carcinogE;nesis model include predominant colon tumors in the distal colon, 
oncogenic mutations at codon 12 of K-ras and H-ras, enhanced cyclooxygenase-2 
and iNOS, microsatellite instability, and some APC mutations (15%) (77). Also, AOM 
is more potent, less expensive and more convenient to use compared to other 
chemicals that are used to induce tumors in animal models. 
Aberrant crypt foci 
Exposure of normal cells to chemical or viral agents results in initiation of the 
carcinogenic process (80). The clonal expansion resulting in altered morphology 
and phenotype of these initiated cells leads to promotion. Further changes in the 
genotype leads to malignancy and metastasis, often defined as the stage of 
progression. Colonocytes act as a barrier against exogenous carcinogenic 
substances. However the biotransformation or the activation/detoxification of the 
exogenous chemicals may lead to preneoplastic or precancerous lesions in the 
colon and rectum called aberrant crypt foci (ACF). ACF were initially identified in the 
colonic mucosa of rodents exposed to colorectal carcinogens and later in human 
colon (80, 81). 
ACF are defined as single or multiple crypts with 1) altered luminal openings 
2) that exhibit thickened epithelia; and 3) are larger than adjacent normal crypts (82). 
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ACF are thus regarded as preneoplastic or precancerous lesions in the large bowel 
of man as well as rodents (83). According to Bird et al the scheme of events starts 
with ACF that selectively go through the multistep process leading to the formation 
of microadenor~as which selectively undergo genetic and other changes to develop 
into adenocarcinomas and carcinomas subsequently (80, 84). ACF can be stratified 
into two broad classes, hyperplastic and dysplastic based on morphology and 
biological behavior. It has been suggested that larger dysplastic ACF are more 
preneoplastic than hyperplastic ACF and are more correlated to tumors (85). ACF 
display a marked biological heterogeneity with respect to genotypic and phenotypic 
features. With increasing time and exposure a higher number of ACF exhibit 
dysplasia and increasing crypt multiplicity. Although, the true neoplastic potential of 
ACF needs to be determined, some of these dysplastic ACF progress into the 
adenoma- carcinoma sequence. Many studies have reported a lack of correlation 
between number of ACF and tumorigenesis (86, 87). Also different 
chemopreventive agents have differential effects. Cholic acid inhibited ACF in rats 
on a short term but increased tumor incidence indicating a lack of correlation with 
ACF and tumors (87). Different initiating or promoting carcinogens such as AOM 
and DMH, time of exposure to carcinogen and the dietary treatments influence the 
number of ACF. Furthermore, ACF that are mucin-depleted and have R-catenin 
accumulation aye more correlated with tumors (88-90). Thus, ACF, although not 
fully committed to neoplasia are preliminary markers of preneoplasia that are easily 
identifiable and hence have been used by many investigators as a short-term marker 
for evaluating chemopreventive compounds against carcinogenesis. 
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Colorectal car~cer and Nonsteroidal anti-inflammatory drugs (NSAIDs) 
The best understood example of NSAID therapy in oncology involves colon 
cancer where multiple lines of evidence, animal and cell culture experiments, 
therapeutic trials and epidemiological studies, all reinforce the conclusion that 
NSAIDs block colon carcinogenesis at an early step (91-96). Epidemiological 
studies indicate a consistent reduced risk of CRC with intake of nonsteroidal anti-
inflammatorydrugs (NSAIDs), including aspirin, by up to 50%(91, 92). Clinical trials 
also demonstrated that sulindac, one of the NSAIDs, caused regression of colorectal 
adenomas in patients with familial adenomatous polyposis (FAP) (97, 98). The well-
supported chemopreventive mechanism of NSAIDs is their inhibition of 
cyclooxygenase (COX) enzymes in the arachidonic acid (AA) cascade. COX-1 and 
COX-2 are the established pharmacological targets of NSAIDs (4, 91, 92, 94, 98, 
99). The pharmacology of NSAIDs and the roles of COX-1 and COX-2 are now 
integrated into a model suggesting that COX-1 synthesizes the housekeeping 
prostaglandins (PG) that protect the stomach lining from ulcers, regulate renal blood 
flow while COX-2, produces PGs that are associated with pain, inflammation and 
fever (94, 98-101) indicating the role of chronic inflammation in carcinogenesis. In 
general, COX-2 is not constitutively expressed in appreciable amounts by most 
normal tissues, but certain inflammatory cytokines, tumor promoters, growth factors 
and oncogenes induce COX-2 (100, 102). 
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Figure 1.3. Arachidonic acid cascade and generation of prostaglandins by COX 
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Arachidonic acid (AA) is the major prostanoid precursor. The biosynthesis of 
prostanoids involves athree-step sequence of stimulus-initiated hydrolysis of 
arachidonate from glycerophospholipids involving secretory, cytoplasmic or both 
types of phospholipase A2 (sPLA2, cPLA2); oxygenation of arachidonate yielding 
cyclic endoperc►xide prostaglandins (PGG) and cyclization catalyzed by the 
endoperoxide synthase component of COX isoenzymes, to yield Prostaglandin H2
and conversion of PGH2 to the most biologically active end products such as PGD2, 
PGEZ, PGF2a, PGIZ (prostacyclin) and TXA2 (thromboxane A2) via specific syntheses 
(Figure 1.3). 
Role of prostaglandins and COX in tumorigenesis 
Certain prostaglandins especially derived by the action of COX-2 isoenzyme 
have been suggested to aid in carcinogenesis by altering normal cellular processes 
like cell proliferation by increasing polyamines and DNA synthesis via ornithine 
decarboxylase <~ctivity, angiogenesis, inhibiting apoptosis, immunomodulation and 
carcinogen metabolism (103). The NSAIDs such as aspirin, indomethacin, sulindac, 
ibuprofen all inhibit both isoforms of COX nonselectively. In vitro and in vivo studies 
indicated different mechanisms of COX inhibition by these classes of drugs. Aspirin 
inhibits the CO~C but not peroxidase activities of both COX-1 and COX-2 by 
acetylating a particular serine thereby blocking the channel leading to the active site 
resulting in irreversible inhibition of PG synthesis. Indomethacin induces an 
inhibitory conformational change by forming a tight, slowly dissociable complex while 
Ibuprofen and piroxicam are competitive inhibitors. In general most of these NSAIDs 
are better inhibitors of COX-1 than COX-2 (103). Although, marked reduced risk of 
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developing colon cancer and its nonmalignant precursor, the adenomatous polyp in 
FAP with NSAIIDs was evidenced, the benefits have not been as obvious in sporadic 
colon cancer as in familial colon cancer (102). Moreover, their prolonged use has 
adverse effects such as nausea, dyspepsia, gastritis, abdominal pain, peptic 
ulceration, gastrointestinal bleeding, and/or perforation of gastroduodenal ulcers and 
nephrotoxicity (98). 
Following the discovery of the COX-2 isoform and with the evidence 
indicating a positive relationship between COX-2 expression and CRC, novel COX-2 
selective inhibitors such as rofecoxib and celecoxib were developed (96, 104-106). 
These were less likely to have the side-effects associated with the general NSAIDs 
including gastrointestinal mucosal defense interference. Evidence from genetic 
studies also demonstrated that deletion of the COX-2 gene resulted in decreased 
tumor formation both in the small intestine and colon of APC mutant models (76). 
This assessment of the role of COX-2 in colorectal tumorigenesis in animal models 
involving knockout mice led to further testing on animal models that suggested a 
regression leading to safer use and prescription of COX-2 inhibitors for FAP patients 
(107-109). Nurnerous studies suggest an initiating event such as a mutation of a 
gatekeeper gene such as APC results in the induction of inflammatory COX-2 while 
COX-1 levels remain the same in normal as well as the tumor tissue (109). 
Although, the reduced gastrointestinal toxicity of COX-2 selective inhibitors favors 
their use, they too have unfavorable side-effects. Rofecoxib, a selective COX-2 
inhibitor has been shown to increase cardiovascular morbidity in some persons and 
was recently taken off the market (110-112) 
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Modulation of COX-2 by estrogen 
COX-2 is induced by inflammatory cytokines, interleukins and 
lipopolysacchar~ides (LPS). There is limited but growing evidence that estrogen may 
influence COX-2 induction. In ovariectomized female rats Ospina et al (113) 
reported the suppression of interleukin (IL-1 R)-mediated induction of the COX-2 
pathway in rat cerebral blood vessels with estradiol treatment. Also, systemic IL-1~3 
induced an NF-xB dependent induction of COX-2 in untreated rats that was blocked 
by estradiol by ,~n ER-dependent mechanism (113). A two-fold increase in COX-2 
mRNA in human uterine microvascular endothelial cells by estradiol was observed 
by Tamura et al (114). Mutoh et al using a R-galactidase reporter gene system 
measured COX-2 promoter-dependent transcriptional activity in human colon cancer 
DLD-1 cells with treatment of genistein and other chemopreventive compounds 
(115) . They observed a suppression of the COX-2 promoter activity with genistein 
and attributed it to the resorcin moiety that is similar to the endogenous estrogen. 
These observations suggest the modulation of COX-2 pathway by estrogens. 
Hypothesis 
The basics concept of cancer prevention involves the regression, inhibition or 
elimination of precancerous lesions leading to reduced cancer incidence. Based on 
our previous findings that clearly showed the effect of dietary estrogens in 
decreasing tumor incidence in AOM-treated mice (36) we wanted to dissect the 
pathways through which estrogen might have an influence in CRC. Numerous 
studies reported decreased colon cancer incidence with NSAIDs and COX-2 specific 
inhibitors (91, 1()7, 115, 116). There is evidence with regard to estrogen modulating 
26 
COX-2 in cerebral blood vessels and uterine tissues from in vitro studies (113, 114). 
There is also evidence indicating that genistein and other chemopreventive 
compounds that have the resorcin motiety in their structure suppressed COX-2 
promoter-depended transcriptional activity in colon cancer cells (115). An increase in 
COX-2 levels is one of the early events in CRC. Hence, we hypothesized that 
dietary estrogens, could reduce CRC risk via inhibition of COX-2. Furthermore, 
these compounds would reduce the formation of ACF, which are morphologically 
determinable lesions that occur during the initiation-promotion stage in the scheme 
of events associated with the multistage carcinogenesis model. We used the AOM-
induced mouse model in which we previously found a positive protective effect of 
estrone. 
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CHAPTER 2 
EXPERIMENTAL DESIGN 
Animal care 
Thirty four 3-week old ovariectomized C57BL/J56 mice purchased from 
Charles River, (Portage, MI were maintained at the animal care facility, located in the 
Human Nutritional Sciences Building in a 25°C, humidity controlled, 12-hour dark-
light cycle environment. Animals were housed 4 to a cage in shoe box plastic 
cages. Mice were acclimated with casein control diet for three days (Table 2.1). At 
4 weeks of age the mice were randomized to the experimental diets with n=7-9 per 
group. All mice were injected intraperitoneally with azoxymethane, at 10 mg/kg of 
body weight once per week for 6 weeks (Figure 2.1). The AOM was administered at 
the same time of day and day of the week. The dose of AOM administration was 
arrived at based on the tolerability of the animals from previous studies and 
effectiveness of the dose (117, 118). Tap water and feed were provided ad libidum. 
Animals were v~reighed weekly and body weights recorded. 
Preparation of Azoxymethane 
Azoxymethane (AOM) was purchased from Sigma-Aldrich, St. Louis, MO. 
The solutions were prepared by careful handling in a fume hood. Twenty five 
milligrams of AOM suspension was mixed in 10 ml of distilled water and aliquots of 2 
ml with a final concentration of 2.5 mg/ml were stored in sealed septum bottles in the 
-20°C freezer. ~On the day of carcinogen injections the dose amount was calculated 
depending on the weight of the mouse with a final dose of 10 mg/kg of body weight 
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Figure 2.1. Experimental design 
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Soy protein without isoflavones (soy-IF) (n=8) 
Soy protein with genistein (soy+gen) (n=9) 
Soy protein with estrone (soy+E~) (n=9) 
* See Table. 2.1 for diet composition 
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Table. 2.1. Composition of experimental diets (AIN93 based) 
Diet Casein Soy-IF Soy+Gen Soy+E1 
g m/kg g m/kg g m/kg g m/kg 
Corn starch 393 396 396 393 
Cellulose BW2002 38 50 49 38 
Phytic acid 15 0 0 0 
Dyetrose3 132 132 132 132 
Sucrose 100 100 100 100 
Casein2 200 0 0 0 
Soy protein w/o I F4 0 200 200 200 
Vitamin mix — AI N 93G2 10 10 10 10 
Salt mix — AI N932 35 35 35 35 
D-L Methionine2 4 4 4 4 
Choline bitartrate2 2.5 2.5 2.5 2.5 
Corn oily 50 50 50 50 
Safflower oil2 20 20 20 20 
Genistein5 0 0 0.25 0 
Estrone 6 0 0 0 0.2* 
* Made with a premix containing 125mg estrone in 250 gm of corn starch (dose of estrone is 
0.093 mg Estrone/kg of diet). Estimated energy content 4.84 kcal/gm of diet 
~ General Stores, 
2 ICN Biomedicals, Inc. (Aurora, OH) 
3 Dyets Inc., Bethlehem, PA 
4 Archer Daniels Midland Inc. (Decatur, I L) 
5 LC Laboratories, Woburn, MA 
6 Sigma-Aldrich, St. Louis, MO 
Diets were prepared in house and pelleted by extrusion at the University of Missouri-
Columbia, MO (Dr. Fu-Hung Hsieh). The diets were color-coded using color laks 
purchased from Monarch Food Colors, High Ridge, MO. 
30 
per mouse. The azoxymethane was administered via intra peritoneal injections 
using a 1 ml syringe and a 27.5 gauge needle. 
Tissue collections 
Mice were anesthetized with Nembutal (50 mg/ml with a dose of 3 mg per 
mouse) between 0800 and 1300 hrs, 6 weeks after the last AOM injection. Amid 
lateral incision was made and the thoracic cavity opened and heart exposed. Blood 
was then collected by cardiac puncture using heparinized (0.01 %heparin) syringes 
and placed in 1.5m1 tubes on ice until centrifuged. Serum was collected after 
centrifugation a~t 14,000 rpm for 7 min and stored in -80°C. Abdominal fat and 
organs including heart, lung, kidney, spleen, cecum and colon were removed and 
weighed. The colon was flushed twice with 1Xrnouse-tonicity phosphate buffered 
saline (MTPBS, 15.7 mM Na2HPO4, 4.5 mM NaH2PO4, 0.15 M NaCI) (119, 120) 
using 18-gauge, bulb-tipped gavage needles. The colon was divided into 2 sections. 
The distal 2 cm section of the colon was sandwiched between 2 microscope slides 
bound by a rubk~er band and fixed in 10% neutral-buffered formalin overnight. The 
remaining part of the colon was scraped using a microscope slide and the 
colonocytes collected in 5X volume lysis buffer (150mM NaCI, 50mM HEPES and 
1%protease inhibitor mix (that had protease inhibitors to inhibit serine, cysteine, and 
calpain proteases), (Amersham Biosciences, Buckinghamshire, UK) snap frozen in 
liquid nitrogen and stored at -80°C until further analysis by Western immunoblot. 
31 
Aberrant crypt foci staining procedure 
The overnight formalin-fixed microscope slides were carefully split apart such 
that the fixed tissue was on the lower slide with the crypts facing up, excess formalin 
was drained with a Kim wipe and the tissue was immersed in (0.2% methylene blue 
stain in distilled water) (82) for 10 min. After rinsing 3X with phosphate buffered 
saline (PBS, 1mM Potassium phosphate monobasic, 0.15M sodium chloride, 5.6mM 
sodium phosphate dibasic anhydrous) for 5 min, cover slips were carefully placed 
on the slides ar~d the crypts were visualized under a light microscope at 10X 
magnification. 
The colon section was outlined on the cover slip using afine-tip marker and 
the aberrant cr\/pts were marked on the cover slip using the marker by two 
independent observers. Aberrant crypts were distinguished from adjacent normal 
crypts by their altered lumina) opening that had thickened epithelia. Some of them 
were elongated) and were distinguishable from the remaining adjacent normal crypts. 
Protein quantification and Western Immunoblotting 
Frozen c;oloncytes were sonicated in short bursts 3X 15 sec apart (Heat 
Systems W-380 sonicator), centrifuged at 120,OOOXg for 30 min at 4°C 
(lJltracentrifuge, Beckman L8-M, Rotor number Ti 50.3) and supernatants collected. 
Protein concentrations of the supernatants were determined using a bicinchoninic 
acid (BCA) kit for protein determination (Sigma, St. Louis, MO). 
Procedure for BCA protein assay: The BCA reagent was prepared by mixing 50 
parts of bicinchoninic acid solution to 1 part of the copper sulfate solution. 
Triplicates of the sample supernatant (dilution factor 10, i.e., 1:10 1 pl of lysate with 9 
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pl of water), Bovine serum albumin (serial dilution of 0.25, 0.5, 1, 1.5 and 2 mg/ml), 
dH2O and the lysis buffer were loaded onto 96-well plate to which 200p1 of the BCA 
reagent was added. The plate was incubated at 37°C for 30 min. The absorbance 
of each well was read at 562nm using the microplate reader. The absorbance 
values were coi~npared to the standard curve to determine the protein concentration. 
Western immunoblot procedure 
Gels were cast on previous day of run using BioRad Mini-Protean 3 cell system (Bio-
Rad, Hercules, CA). The first 4 solutions (Table 2.2) were mixed and degassed for 
15 min. The cress linking agents were added immediately before transfer into the 
gel apparatus. A layer of water was placed over the separating gel until it was set. 
The water was wiped off with a Kim wipe and the stacking gel layered on top. A 
comb was inserted into the gel and allowed to set. The wells were rinsed with water 
prior to sample loading. From the determined concentrations of the supernatant 
sample 5µg of protein was loaded per wells. The supernatant was mixed with 6X 
sample buffer (1.5M Tris-HCI, glycerol, sodium dodecylsulfate (SDS), dithiothreitol 
(DTT), bromophenol blue) to yield a total volume of 30µI and heated at 100 °C for 1 
min. The loading concentration of the supernatant was determined empirically. A 
COX-2 standard (positive control) (Sigma, St. Louis, MO) an internal control (a 
sample supernatant that was repeated in all the gels) and a molecular weight 
standard (Bio-Fad, Hercules, CA) were run on each gel. Proteins were separated 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% 
separating gel with a 4% stacking gel (Table 2.2) at 200 V until the dye 
(bromophenol hlue) ran off the bottom. 
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Table 2.2. Reagents used for casting the gel for western immunobiot 
FOR 2 MINIGELS (1.5mm thick) 10 %resolving 4% stacking 
30% Acrylamide/0.8% Bis solution 6ml 0.67 ml 
1.5M Tris, pH 8.82 5 ml - 
0.5M Tris pH 6.83 1.25 ml 
d H2O 8.10 m l 3.07 m l 
10% SDS~ 200u1 50 ul 
TEMED ~ (N, N, N, N —tetra-methyl-
eth lenediamine Y ) 20u1 5 ul 
10% Ammonium Persulphate2 100u1 25 ul 
1 Bio-Rad, Hercules, CA 
2 Fisher Scientific, Fairlawn, NJ 
Typically the gE~l ran for about 50 min to an hour. The gel was carefully removed 
from the glass plates and incubated in the transfer buffer (25 mM Tris, 192 mM 
glycine, 20% methanol) along with the filter pads, filter paper and nitrocellulose 
membrane (Tr~~ns-Blot transfer medium, Bio-Rad, Hercules, CA) for 30 min. The 
electrophoresis and transfer were carried out with PowerPacTM HC Power supply 
(Bio-Rad, Hercules, CA) and Bio-Rad Mini Trans-Blot system (Bio-Rad, Hercules, 
CA). The transfer was done for 90 min at 100 v constant voltages. The membranes 
were then incubated for 2 hr at room temperature on a rocker in a blocking buffer 
(1.5% non-fat dry milk and 1.5% Bovine serum albumin (BSA) in Tris Buffered Saline 
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(TBS) 0.5mM Tris base, 0.9% NaCI). The membrane was cut into 2 pieces based 
on molecular weight using the colored standards as a guide. The upper part of the 
membrane was incubated with mouse monoclonal anti-COX-2 antibody (1:10,000). 
The lower part was incubated in mouse monoclonal anti-(3-tubulin antibody 
(1:10,000) in block buffer overnight at 4° C on a rocker. Membranes were washed 4 
X 5 min with TESS and probed with goat anti-mouse IgG-HRP conjugate (COX-2 
1:50,000; R-tubulin 1:5000). Table 2.3 lists the antibodies and reagents used in 
these analyses. Target proteins were detected using Pierce West Femto Maximum 
Sensitivity substrate and quantified with a Bio-Rad GS-800 Densitometer using 
Quantity One software. ~3-tubulin served as the loading control. For each sample 
the density of COX-2 was normalized with the density of the corresponding R-tubulin 
and then a correction for intergel comparison was done using the internal sample 
control. To generate a correction factor the COX-2/~3-tubulin ratio for the internal 
sample control was determined for each gel then an average derived. This average 
was divided by the individual gel internal sample control ratio and used as the 
correction factor as follows 
Normalized C O►X-2 sample 
~CC)X-2 sample ~ 
R-tubulin 
Correction factor 
Statistical analysis using SAS (SAS Institute, Cary, NC) was performed on this 
normalized COX-2 value. We used Proc mixed procedure of SAS to do one way 
analysis of variance (1-way ANOVA) on normalized COX-2 value and the mean 
number of ACF per diet group. The organ weight data as percent of body weight 
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was analyzed using the General Linear Model (GLM) procedure. Differences among 
means were determined by the least square (LS) means component. Pair wise 
comparison usi~~g Tukey-Kramer was done. The body weight data was analyzed 
using the Proc mixed procedure while the last two week differences were done after 
Bonferroni adjustments. Main effect and interactions were considered significant at 
P<_ 0.05 for COX-2 protein density levels and number of ACF after Tukey-Kramer 
adjustments. Measurements were reported as mean ±SE. 
36 
Table 2.3. Antibodies and reagents used for COX-2 western immunoblot 
Catalog 
No. 
Source Dilutions Comments 
Molecular 161- Bio-Rad Kaleidoscope prestained standards 
weight 
marker 
0324 control 
Cox-2 std C-0858 Sigma Human, recombinant expressed in 
Sf21 cells 
Molecular weight of COX-2 72 kDa 
Primary ~~C- Santa 1:10,000 Mouse monoclonal IgG 200ug/ml 
Cox-2 
antibody 
19999 Cruz 
Biotech-
nology 
Inc. 
Secondary 
antibody 
SC-2005 Santa 
Cruz 
1:50,000 Goat anti-mouse igG-HRP 
Biotech-
nology 
Inc. 
Primary SC-5274 Santa 1:10,000 Mouse monoclonal 
antibody 
for ~- 
tubulin 
Cruz 
Biotech-
nology 
Molecular weight of ~-tubulin 55kDa 
Inc. 
West 
Femto 
34094 Pierce 1:1 Super signal West Femto maximum 
sensitivity substrate 
Substrate 
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ABSTRACT 
Epidemiological studies indicate a lesser incidence of colon cancer in 
populations that consume fruits, vegetables and vegetable proteins such as legumes 
over the western diets that are rich in animal protein and fats. Soy and associated 
bioactive substances such as the isoflavones have been associated with lower colon 
cancer risk. W~ previously found reduced colon tumor incidence in mice fed soy 
protein with estrone (E1). Several epidemiological studies indicate a 40-50% 
reduction in the risk of developing colorectal cancer with chronic non-steroidal anti- 
inflammatory drugs (NSAIDS) including aspirin that inhibit both isoforms of the 
cyclooxygenase (COX) enzyme COX-1 and COX-2. We hypothesized that dietary 
genistein, or estrone (E1) would reduce aberrant crypt foci (ACF), a purported 
preneoplastic marker, and COX-2 protein levels in mice colon. Ovariectomized 
female mice were fed diets containing casein (Casein), soy protein without 
isoflavones (Soy-IF), soy protein + genistein (Soy+Gen) or soy protein + estrone 
(Soy+E1) from 3 weeks of age. Beginning at 4 weeks of age, all animals received 
weekly injections of azoxymethane (AOM) 10mg/kg of body weight for 6 weeks and 
terminated 6 weeks after the last dose of AOM. Aberrant crypt foci were visualized 
under a light microscope and COX-2 protein levels were analyzed by Western 
immunoblot. COX-2 protein levels were affected by diet (P<_ 0.05) but aberrant crypt 
foci incidence was not (P<_ 0.05). COX-2 levels were lower in mice fed Soy+E1 and 
Soy+Gen compared with mice fed the casein or Soy-IF. Thus, we conclude that soy 
protein with genistein ad soy protein with estrone downregulate COX-2 levels and 
may thereby reduce colon cancer risk. 
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INTRODUCTION 
Cancer accounts for approximately 23% of all deaths in the United States, 
ranking second only to heart disease. Colon cancer is the third most commonly 
diagnosed cancer among men and women (1, 2). In 2005 estimated new cases of 
colon cancer were 48,290 for men and 56,660 for women (1, 2). Colon cancer risk 
is influenced by various environmental factors such as exposure to chemicals, 
radiation, smoking, oxidative damage, and other lifestyle factors such as physical 
activity, and alcohol intake (3). Epidemiological data suggest that diet plays a major 
role in the etiology of colon cancer (4, 5). The World Cancer Research Fund and the 
American Institute of Cancer Research after an extensive review of literature 
concluded that colon cancer risk was reduced with vegetable intake, and physical 
activity while consumption of red meat (probably the associated saturated fat) and 
alcohol increased the risk (6). COlon cancer incidence rates among populations 
differ greatly with the lowest incidence in the Asian population (2, 7, 8). However, 
the incidence rates of colon cancer among the migrant Asian population to the 
United States reach those of the host country implicating the role of environment in 
the incidence of colon cancer(?-10). One plausible reason for the difference in 
incidence rates was attributed to the consumption of soy by Asian population (7). 
Soy is a good source of several phytochemicals, including the isoflavones genistein 
and daidzein, in addition to the high quality protein (6, 9, 11). The structural 
similarity of isoflavones to that of endogenous estrogen and their weak estrogenic 
property classified them as phytoestrogens (12, 13). 
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A role of hormones in the etiology of colon cancer was observed first by 
Fraumeni et al who noted that nuns experienced an excess of known hormone- 
associated cancers and also colon cancer (14). Ameta-analysis of 18 
epidemiological studies indicated a 20% reduction in colon cancer risk with hormone 
replacement therapy (HRT) (15). Furthermore, evidence from the Women's Health 
Initiative (WHI) also indicated that estrogen reduced the risk for colon cancer (16, 
17). However, subjects in that study who developed colon cancer were diagnosed 
with more advanced stages of colon cancer when using HRT compared to the 
placebo (16). 
Several epidemiological and case-controlled studies indicate an inverse 
association between the risk of colon cancer and intake of NSAIDs, including aspirin. 
(18). The decrease or regression of colon carcinogenesis by NSAIDs has been 
attributed to the specific inhibition of the cyclooxygenase (COX) enzymes by these 
classes of drugs. COX catalyzes the committed step in prostaglandin synthesis. 
Two isoforms of COX (COX-1 and COX-2) are known (19, 20). COX-1 is a 
constitutively expressed enzyme and has a housekeeping role helping to maintain 
physiological functions such as cytoprotection and blood flow (21). COX-2 is 
inducible as it is dependent on extracellular and intracellular stimuli and is 
upregulated with inflammation (22) cellular proliferation, differentiation, and 
tumorigenesis (23, 24). The suppression of COX-2 induction by interleukin 1 ~3 (IL- 
1 R) with chronic treatment of 17R-estradiol in rat cerebral vascular blood vessel 
suggests a role for estrogen in modulating COX-2 (25). Moreover, there is also 
evidence suggesting a strong link between COX/PGE2 (Prostaglandin E2) signaling 
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and the adenomatous polyposis coli (APC)/~3-catenin/TCF pathway by estrogen 
whose downstream target protein includes COX-2 (26-28). There is further evidence 
implicating the regulation of COX-2 by the Wnt and Ras pathways suggesting a 
cross talk between the pathways involving estrogen in colon carcinogenesis (29). 
Thus, regulation/inhibition of COX-2 by estrogenic compounds would be an effective 
way to inhibit colon carcinogenesis in the initial stages of the multistage 
carcinogenesis. 
Previously we showed that estrone (E1) was protective against colon 
tumorigenesis in mice treated with azoxymethane (30). In this study we evaluated 
the hypothesis that genistein reduces COX-2 and protects against azoxymethane 
(AOM) induced aberrant crypt foci (ACF) formation in mice. 
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MATERIALS AND METHODS 
Chemicals: Azoxymethane (AOM) was obtained from Sigma-Aldrich (St. Louis, MO) 
in 10 mg isovials and stored at -20°C which was resuspended in 10m1 distilled water. 
Genistein and Estrone (E1) were obtained from LC Laboratories (Woburn, MA) and 
Sigma-Aldrich (St. Louis, MO) respectively. 
Animals, diet and study design: The experimental protocol was approved by the 
Institutional Animal Care and Use Committee, Iowa State University and followed 
AAALAC standards. Thirty four female ovariectomized (3wks of age) C57BL/J6 
mice (Charles River, Portage, MI) were housed 4 per cage and maintained in a 
temperature and humidity controlled animal facility with a 12 hr light cycle. Animals 
were fed a modified AIN93G diet containing casein as the protein source for 3 days 
of acclimatization, after which they were assigned randomly to one of the four diet 
groups; Casein (n=8) as control, soy protein without Isoflavones (IF) (Soy-IF) (n=8), 
soy with genistein (Soy+Gen) (n=9) and soy with estrone (Soy+E1) (n=9) (Table. 
2.1). The diets were isocaloric and the soy protein was treated by the manufacturer 
(Archer Daniels Midland (Decatur, IL) to remove the majority of the isoflavones (IF). 
The same lot and batch of protein was used for all of the diets containing soy protein 
as the protein source. The dose of genistein (250mg/kg diet) was based on our 
previous finding of delayed mammary tumorigenesis in mice fed this concentration 
(31). The dose of E1 was extrapolated from the typical human HRT dose for 
Premarin (0.625 mg/d) and shown to reduce tumor incidence previously (30). 
Casein diet was corrected for the concentration of phytate in the soy protein diet. 
Beginning at 4 wks of age, the mice were injected intraperitoneally with 10 mg 
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azoxymethane (AOM; Sigma-Aldrich (St. Louis, MO) /kg body weight once a week 
for 6 wks. AOM injections were done at the same time of day throughout the study. 
Tissue sample collection 
Mice were anesthetized with Nembutal (Iowa State University veterinary pharmacy, 
Ames, IA, 3 mg per mouse) between 0800 and 1300 hrs, 6 weeks after the last AOM 
injection. A midlateral incision was made and the intestinal tract removed. The 
colon was rinsed, blotted, weighed and opened longitudinally. The colon was 
divided into 2 sections. The distal section of 2 cm length was fixed with 10% neutral 
formalin sandwiched between 2 microscope slides overnight. The remaining part of 
the colon was scraped with a microscope slide and the colonocytes collected in lysis 
buffer (150mM Nacl , 50mM Hepes and 1 %protease inhibitor mix) snap frozen in 
liquid nitrogen and stored in -80~C until used for Western blot analysis. Abdominal 
fat along with liver, cecum, spleen, heart and kidney were removed and weighed. 
Aberrant crypt foci 
Aberrant crypt foci (ACF) are altered lumina) openings with morphologically altered 
crypts in AOM induced rodents (32). After fixing overnight the distal colon was 
dipped in 0.2% solution of methylene blue in distilled water for 10 min rinsed with 
phosphate buffered saline for 5 min 2X and placed on a microscope slide with the 
mucosal surface up. Using a light microscope at 10X magnification, aberrant crypts 
were distinguished from the surrounding "normal-appearing" crypts using standard 
criteria and counted by two independent observers. 
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Quantification of Cyclooxygenase-2 by immunoblot 
Frozen homogenates of colonocytes were sonicated and centrifuged at 120,000 X g 
for 30 min at 4°C and the supernatants collected. Protein concentration of the 
supernatants was determined with the BCA protein assay kit (Sigma, St. Louis, MO). 
Protein extracts (5µg) were mixed with loading buffer, denatured and fractionated on 
10% SDS-polyacrylamide gels and then electrophoretically transferred to 
Nitrocellulose (Bio-Rad). On each gel, were included a prestained molecular weight 
color marker mix (Bio-Rad, Hercules, CA), a positive control of COX-2 (Sigma, St. 
Louis, MO) and an internal sample control comprised of a single mouse supernatant. 
After transfer, the membranes were blocked in 1.5% non-fat dry milk (Blotto; Santa 
Cruz Biotechnologies, Santa Cruz, CA) and 1.5% Bovine Serum Albumin (BSA) 
(Sigma, St. Louis, MO) for 2 hrs on a rocker at room temperature. Membranes 
were cut into 2 pieces based on molecular weight using the color bands from the 
prestained molecular weight marker. The individual strips were incubated with either 
mouse monoclonal anti-COX-2 antibody (1:10,000; Santa Cruz Biotechnology, 
Santa Cruz, CA) or mouse monoclonal anti-~-tubulin antibody (1:10,000; Santa Cruz 
Biotechnology) in blocking solution overnight at 4° C. Membranes were washed with 
Tris buffered saline (TBS) then probed with goat anti-mouse IgG-HRP conjugate 
(COX-2 1:50,000; ~-tubulin 1:5000; Santa Cruz Biotechnology). Target proteins were 
detected with West Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL). 
The membrane was scanned and quantified with aBio-Rad GS-800 Densitometer 
(Bio-Rad Lab, Hercules, CA) using Quantity One software (Bio-Rad, Hercules, CA). 
~—tubulin served as the loading control. For each sample the ratio of sample COX-2 
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and the corresponding R-tubulin density was determined. A correction for intergel 
comparison was done using the internal sample control. To generate the correction 
factor, the internal sample control ratio of COX-2 and ~3-tubulin for each gel was 
determined and then an average across all gels was obtained. That average was 
divided by the individual gel internal sample control ratio and then used as a 
correction factor as follows 
N o rm a I ized COX-2 sample 
COX-2 sample ~ 
~-tU b U l l n sample 
~ J 
Correction 
A representative immunoblot is shown in Figure 3.1. Note the internal sample 
control and the COX-2 standard (std). 
Statistical analysis: Proc Mixed procedure was used to analyze aberrant crypt foci 
and COX-2 protein levels by one way analysis of variance (ANOVA). The body 
weight was analyzed using the Proc Mixed procedure while the organ weight data 
was analyzed vuith the General Linear Models (GLM) procedure of SAS (SAS 
Institute, Cary, NC). Differences among means were determined by the least- 
square (LS) Means component. Main effects and interactions were considered 
significant at P<_0.005 for organ weights and P<_0.05 for COX-2 protein density levels 
and number of ACFs after Tukey-Kramer adjustments. All measurements are 
reported as the mean ±SE. 
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RESULTS 
Mice fed the experiu~nental diets gained weight similarly throughout the study 
(Figure 3.2). However, slight differences in body weight due to diet were observed 
at termination (Table 3.1). The differences in body weight occurred during the last 2 
weeks of the study (Figure 3.2). Mice fed Soy-IF weighed slightly more than 
Soy+Gen at these time points. Mice fed Soy-IF had more abdominal fat than the 
Soy+Gen animals, which might explain this difference in body weight (Figure 3.3). 
When expressed as percent of body weight, colon, kidney, spleen weights were less 
in mice fed Soy-IF compared to Soy+E1 animals, and cecum weights were less in 
this Soy-IF group compared to all the diet groups (Table 3.1) (P<0.005) 
Aberrant crypt foci (ACF) 
ACF were observed in all mice irrespective of diet groups. The mean ACF ranged 
from 5-8 in each group. There was no significant statistical difference in the number 
of ACF across the four diet groups although the Soy+Gen group tended to have 
more number of ACF than the other diet groups (Figure 3.4). 
Cyclooxygenase-2 protein 
COX-2 protein levels as determined by western immunoblot in mice fed the Soy+E1 
or Soy+Gen were significantly less (P <_ 0.01) compared to the mice fed the Casein 
or Soy-IF diets (Figure. 3.5) 
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DISCUSSION 
The FDA recently approved a health claim for foods containing soy and 
recommended 25 g of soy protein per day to reduce cardiovascular disease risk 
(11). Some other health benefits associated with soy and soy foods include 
decreased bone loss and alleviation of menopausal symptoms. As a result, soy 
consumption is increasing in the United States. Also, many peri and 
postmenopausal women are using soy supplements or soy extracts that contain 
isoflavones to alleviate menopausal symptoms as an alternative to hormone 
replacement therapy (HF~T). Epidemiological studies have indicated associations 
between HRT and reproductive history with colon cancer risk, suggesting a role for 
estrogenic compounds in decreasing colon cancer risk (10, 16, 33-35). 
COX-2 has emerged as therapeutic and chemopreventive target for colon 
cancer with epidemiological and clinical studies indicating COX-2 inhibition is 
protective of colon cancer (22, 23, 36-39). Although the evidence is limited, COX- 
2 may be influenced by estrogens (25, 40). Hence the objective of this short term 
study was to determine i'f dietary genistein or estrone would affect COX-2 
expression in azoxymethane-treated mouse colon. We also used ACF as a pre- 
tumor marker. ACF has been widely used as an early indicator of tumorigenesis by 
many short-term studies (41). In this study we found no diet effect on ACF. This 
result contradicts with two other studies. A reduction in ACF was observed in 
AOM-treated rats fed soy concentrate with genistein than the soy concentrate alone 
diet (42). And Gee et al (32) reported an increase in the number of ACF in 
dimethylhydrazine-treated rats fed purified genistein or genistein-rich soy protein . 
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We previously showed mice fed Soy+E1 had lower tumor incidence than mice fed 
Soy-IF (30). Therefore the lack of response in ACF in this study by Soy+E1 was 
surprising. However, many studies reported conflicting results on the association 
between ACF and tumorigenesis (43-46). Certain dietary compounds such as 
cholic acid and 2-(Carboxyphenyl)retinamide 2-CPR are potent inhibitors of ACF 
formation but cause higher incidence of tumor formation in rats leading to 
conflicting correlation between ACF and tumors. It is not clear if ACF are true 
markers of tumor development and the current study would suggest that at least in 
the AOM-treated C57BL/J6 mice they are not. 
No difference in tumorigenesis was reported in APCmin mice fed soy protein 
with high or low isoflavorie supplementation (47). The diets fed to these mice were 
high in animal fat and lovv in fiber and calcium similar to a western diet, which could 
be a possible explanation for the lack of any effect. However, the number of small 
intestinal tumors in these mice was significantly reduced with a low isoflavone diet 
containing 300ppm of sulindac, a NSAID (47). In our study the addition of genistein 
to soy protein did not have an effect on ACF while Thiagarajan et al (42) found a 
smaller dose of genisteir~ (167mg/kg diet) with soy concentrate reduced ACF by 
50% in AOM-treated rats. 
The need for a better reliable preneoplastic marker is strongly emerging with 
these conflicting results. Yamada et al (48) proposed the use of ACF with 
~3-catenin/APC mutations that result in ~3-catenin nuclearization and dysregulation of 
the wnt signaling pathway as a better preneoplastic marker. They proposed that 
the dysplastic ACF that are mucin-depleted and have R-catenin accumulation in the 
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nucleus are more correlated with tumorigenesis (49). We attempted to identify 
mucin depleted foci in the distal colon of mice from the current study using alcian 
blue stain in 3% acetic acid. However, we were unable to clearly distinguish the 
mucin depleted foci from the surrounding crypts. This may have been due to the 
number of ACF with mucin depletion to be only about 1-2% (refer Figure 4.1) and 
with the incidence of about 5-8 ACF per mouse in our current study the probability 
of us visualizing the mucin depleted foci is very low. 
Previously we reported the reduction of colon tumorigenesis in mice fed 
Soy+E1 that innplicated the role of estrogen in colon carcinogenesis (30). We also 
observed a tendency for reduction in tumor incidence in the Soy+Gen group, 
although not statistically significant, thus indicating a trend towards lower colon 
cancer incidence with estrogen-like compounds. This is supported by the finding of 
Javid et al (50) who reported prevention of intestinal tumorigenesis in 
ovariectomized APCm"' mice treated with estradiol . 
Our current observation of a significant reduction in COX-2 protein levels in 
mice fed genistein or est~one suggests a protective action of estrogens may be 
mediated through attenuation of COX-2 protein levels. This finding contradicts a 
previous report that geni~tein added to a casein diet had no effect on tumorigenesis 
in AOM-treated rats and increased tumor multiplicity (51). They also observed no 
effect on COX-2 activity and a significant suppressive effect on 15-PGDH (15- 
hydroxyprostaglandin Fla dehydrogenase) activity by genistein. Several 
differences in our study may provide explanation for these opposing results. Our 
study was done using ovariectomized female mice, whereas Rao et al (51) used 
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male rats (47, 51). It is possible that the response to AOM and/or the dietary 
treatments differs between males and females and between rats and mice. 
Moreover, the synergistic effect of soy protein with estrogenic compounds 
compared to the casein-k~ased diet with added genistein (51) might explain the 
differences. 
The primary therapy for patients with hereditary nonpolyposis colorectal 
cancer (HNPCC) and familial adenomatous polyposis (FAP) are the selective COX- 
2 inhibitors (23, 28, 36, 38). Recently, COX inhibitors have been taken off the 
market because of serious side-effects including cardiovascular risks (52, 53). The 
need for alternative COX-2 inhibitors without side-effects makes this study of 
significance for further research. COX-2 is the rate limiting step in the generation of 
prostaglandins including PGE2 and PGF2a (19, 36, 54). These prostanoids 
mediate cellular proliferation via the wnt or Ras signaling pathways (29). Although, 
the precise mechanism by which estrogens affect COX-2 levels in not known, 
several mechanisms may be proposed. One hypothesis is that genistein and E1 
mediate their ~rrotective effects via estrogen receptors ERa or ERR (28, 30, 55). A 
77% increase un tumorig~nesis was reported in ovariectomized Min/+ mice 
compared to controls that were treated with 17(3-estradiol (56). Another hypothesis 
is that estrogen might influence through ER-independent pathways such as the wnt 
signaling pathway (27). 
Genistein has been extensively studied and many proposed modes of action 
have been proposed apart from its phytoestrogenic activity in the regulation of cell 
growth (57). In the present study, we observed inhibition of COX-2 protein levels in 
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response to short term feeding of genistein. It would be interesting to observe the 
effects of genistein with chronic administration and to measure COX-2 protein 
levels as well as activity. More studies elucidating the mode of action of genistein 
with regard to dosage, time of exposure in combination with other dietary factors 
such as soy are essential to understand the role of genistein and estrogenic 
compounds and their synergistic effect in colorectal carcinogenesis. 
In conclusion, we found that dietary genistein and estrone significantly 
reduced COX-2 protein levels in AOM-treated C57BL/J6 mouse colon. The 
mechanism of action leading to attenuation of COX-2 protein levels remain to be 
elucidated. It is likely that the effect of genistein in reducing COX-2 protein levels is 
mediated via an ER-dependent pathway. However, the possibility of a cross talk 
between the wnt signaling pathways, tyrosine protein kinase pathway cannot be 
ruled out. 
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Figure legends: 
Figure 3.1. A representative immunoblot in azoxymethane (AOM) treated colonic 
mucosa of mouse. An internal standard comprised of a sample that was run on 
each gel (R), as was the C:OX-2 standard (std) 
Figure 3.2. Body weight of mice fed experimental diets 
Figure 3.3. Body weight of mice at 14 and 15 weeks of age. Mice fed Soy-IF 
weighed more than the Soy+Gen mice at these time points. P<_0.006 
Figure 3.4. Abdominal fat expressed as percent of body weight in mice fed the 
experimental diets. Mice fed Soy+IF had more fat compared to mice fed Soy+Gen 
P<_0.005 
Figure 3.5. Mean number of Aberrant crypt foci (ACF) in mice fed experimental 
diets. Total number of ACF in each diet group was determined by 2 independent 
observers. Data expressed as mean with standard error shown in T bars. There 
was no significant difference (P<_ 0.05) due to diet treatment. 
Figure. 3.6 Effect of experimental diets on COX-2 protein levels in azoxymethane 
(AOM) injected mice. Different letters on the bars represent significant differences 
among diets (P<_ 0.01). There was no difference with Casein and Soy-IF diet group. 
55 
* Indicates a significant difference between casein and Soy+E1 (P<_ 0.004) and 
Casein and Soy+Gen (P<_ 0.006) in the least square mean of 9 rats ± SEM. 
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Figure 3.1 A representative immunoblot 
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Figure 3.2. Body weight gain of mice fed experimental diets 
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Figure 3.3. Body weight of mice at 14 and 15 weeks of age 
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Figure 3.4 Abdominal fat expressed a~► a percent of body weight 
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Figure 3.5 Mean number of Aberrant crypts across different diet groups 
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Figure 3.6 Quantification of COX-2 protein expression in mice fed experimental diet 
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CHAPTER4 
DISCUSSION 
It has been suggested that populations that consume soy have decreased 
incidence of CRC (1, 2, 4, 28). However, epidemiological and animal studies 
examining the relationship of soy and soy isoflavone intake and risk of CRC have 
produced conflicting results (28, 41, 42) (Table 1.1). Some epidemiological and 
case controlled studies have looked for a role for estrogen in CRC (45, 128, 128). 
For example, the outcome of the Women's Health Initiative (WHI) trial provided 
evidence for a protective role for estrogen in colon cancer risk with a 20% reduction 
in CRC (47, 49). However, animal studies are a means to deduce the direct role of 
estrogen and estrogenic compounds such as phytoestrogens (genistein) in the 
molecular mechanism of CRC. One possible mechanism for estrogen to affect CRC 
is through COX-2. NSAIDs and COX-2 inhibitors are the primary therapy for FAP 
patients and have been shown to decrease or regress CRC (130, 131). Although, 
there is evidence of estrogen influencing COX-2 in cerebral blood vessels (113), 
vascular system (114) and uterine tissues (138), the correlation between estrogens 
and COX-2 in colon has not been examined. Previously, we found diets 
containing soy protein with estrone decreased tumor incidence in mice (36). To 
further elucidate whether estrogen's influence on CRC is via suppression of COX-2 
protein levels, this short term study was conducted. 
Optimization of Western blot technique 
In order to develop the methodology to quantify the COX-2 protein levels by 
western immunoblot (WIB) we ran several trials using samples obtained from mice 
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that had been treated with AOM for one or two weeks. As part of the method 
refinement, the lysis buffer used to collect the colonocytes was arrived at after 
several trials using lysis buffers from Singh et al (139) and Davidson et al (140). 
Initial attempts to detect COX-2 protein were discouraging as we were able to detect 
only the positive control (Sigma, St. Louis, MO). Further trials with another positive 
control from Cayman Chemicals, Ann Arbor, MI and primary antibody also yielded 
mixed results. (Positive control —Catalog no. 160126, 10004910, primary antibody 
catalog no. 160'106). We were able to detect only the positive control when loaded 
in high amounts. We also attempted to load greater than 150 pg of protein into each 
well. We tried different detection systems such as Super signal West Pico mouse 
IgG detection kit (Pierce, Rockford, IL), ECL plus western blotting detection system 
(Amersham Biosciences, Buckinghamshire, UK). We concluded that the amount of 
COX-2 expressed is too low in mouse colon samples. However, the Pierce West 
Femto Super sensitivy substrate yielded good detection of the COX-2 protein in the 
samples along with the positive control of COX-2 from Sigma, St. Louis, MO. This 
protocol allowed us to consistently visualize COX-2 in our samples. We relied on 
one mouse sample as an internal sample control that was repeated in each gel to 
adjust film exposure time to minimize inter-gel variance. We also optimized the 
protocol for ~3-tubulin to be used as a loading control for each sample. 
Quantification of COX-2 protein levels in samples 
In the WIB experiments each sample was repeated twice and the average of the 
normalized values was used for statistical analysis. To normalize, the OD ratio of 
COX-2 and its corresponding ~3-tubulin value for each sample was determined and 
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then a correction for inter gel variation done using the internal sample control. To 
generate the correction factor the ratio across all gels of the COX-2 and 
corresponding ~i-tubulin of internal sample control was averaged. Then the ratio of 
this average value to the individual internal sample control value for an individual gel 
was calculated and used as a correction factor to normalize the COX-2 OD for each 
sample. 
We determined the coefficient of variance of repeat measures to check for the 
repeatability of the WIB with the same samples. To arrive at the coefficient of 
variance we averaged the OD of internal sample control value across all gels and 
determined the standard deviation. The percentage ratio of standard deviation to 
mean gave the coefficient of variance. The inter gel variation of COX-2 was 13% 
which is a very low variation. The intra gel variation was (<2%) suggesting little 
variance in loading as well as repeatability of the WIB. (Table 5.1) shows the mean 
and the standard deviation of the internal standard control across the gels and the 
coefficient of variance obtained in percent. 
We also did a paired t-test and cone-way analysis of variance test to account 
for variability for the repeatability of measure values between the samples and within 
the samples which gave a low variance (0.045) suggesting little variability between 
repeatability. 
Our hypothesis that dietary estrogens (estrone and genistein) suppresses the 
COX-2 protein levels in colon was demonstrated with a significant decrease in COX-
2 levels in the mice fed estrone and genistein with soy protein in this short term 
study. To our knowledge this is the first study that demonstrated that oral dietary 
estrogens influence COX-2 protein levels in colon of mice. This observation is 
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supporting our earlier report of decreased tumor incidence in mice fed estrone 
suggesting the protective effect of estrone being mediated by suppression of COX-2. 
This finding is also in line with earlier reports of Singh et al (139) who reported the 
modulation of COX-2 protein levels in AOM-treated rat colon by high fat corn oil and 
high fat fish oil diet. The high fat fish oil decreased COX-2 expression in colon 
mucosa and tumors but a reverse effect was seen with high fat corn oil. However, 
they did not observe the effect of dietary estrogens on colon of mice. Another report 
from the same group contradicts our observation of suppression of COX-2 by dietary 
genistein. In AOM-treated rats fed casein based genistein diet an increase in tumor 
multiplicity with no effect on COX-2 activity and tumor incidence was reported (38). 
They also reported a significant suppressive effect on 15-PGDH (15-
hydroxyprostaglandin Fla dehydrogenase) activity by genistein. Several differences 
in our study may provide explanation for these opposing results. Our study was 
done using ovariectomized female mice compared to male rats. Differences in 
response to AOM, the dietary treatments before and after carcinogenic treatment 
and response due to gender difference might have influenced the outcome. It is also 
important to note that they did not measure the COX-2 protein levels or the PGE2 
levels, the major PG that has been demonstrated to influence tumorigenesis. They 
had measured 8-isoprostane that is similar to PG and is generated by nonenzymatic 
metabolism of AA (103) 
Our observation of suppression of COX-2 by dietary estrogens is novel and 
has potential significance. The precise mechanisms by which estrogens mediate 
this effect are not clearly known. Several hypotheses to explain this observation are 
possible. One hypothesis is that the dietary estrogens mediate their suppressive 
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effects via ER, possibly by ERR. Normal human colon expresses both ERa and ER~3 
but ER~3 appears to be the dominant receptor in the colon that is selectively lost in 
malignant tissues (51-53). Ospina et al (113) observed repression of COX-2 gene 
by estradiol in cerebral blood vessel when stimulated with IL-~3 in a ER dependent 
manner. Also, in human uterine microvascular endothelial cells that expressed ER~3 
mRNA and protein abundantly, treatment of estradiol (10-10 to 10"6 M) increased 
COX-2 mRNA levels by 2.3 fold suggesting upregulation of COX-2 being mediated 
in an ER dependent pathway (114). 
In human colon cancer DLD-1 cells genistein and other chemopreventive 
compounds including resveratrol and quercetin having resorcin moiety suppressed 
the COX-2 promoter activity with and without TGFa- stimulation suggesting 
modulation at the promoter level by these estrogen like compounds (115). 
Furthermore, Hertrampf et al (138) reported tissue specific modulation of COX-2 
expression in the uterus and vena cava by estrogens and phytoestrogens. They 
found that administration of 173-estradiol (3~g/mg body weight/day for 3 days) in 
ovariectomized female rats stimulated COX-2 mRNA expression in the uterus but 
downregulated in the vena cava. Also adose-dependent downregulation of COX-2 
in vena cava was observed with administration of genistein at very low dose (0.5 
mg/kg of body weight) with no effect in the uterus. These studies suggest a 
transcriptional effect of estrogenic compounds on COX-2 (115). There is also some 
evidence suggesting regulation of COX-2 mRNA expression by at least two different 
molecular mechanisms including modulation of the transcription rate of the gene 
and/or by post-transcriptional regulation of mRNA stability (141). It is possible that 
estrogen is influencing this effect in an ER dependent pathway. Also, the two 
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receptors (ERa and ER~3) may function in opposite ways in modulating the effects of 
estrogen. The presence of different isoforms of ERR as well as the ability of ER to 
form homo or heterodimers suggests a complex mechanism that involves tissue 
specific modulation of COX-2 by estrogen. These ligand (estrogen/phytoestrogen) 
bound ER form a stable dimer that then interacts with specific estrogen response 
elements to modulate the transcription of target genes. 
Another hypothesis is that genistein and estrone alter ER-independent 
pathways in the colon. Weak estrogenicity of genistein and its other purported 
properties in inhibiting tyrosine kinases (29), DNA topoisomerases (142) and 
regulation of cell growth might possibly mediate this suppressive effect. However, 
our data does not address this concept that genistein suppresses COX-2 via 
inhibition of intracellular signaling pathways related to tyrosine kinases or DNA 
topoisomerases. Moreover, estrogen can also mediate its effect via nonnuclear 
estrogen-signaling pathway. These cell membrane receptors that are suggested to 
be similar to intracellular ER are located in cell membrane invaginations called 
caveola and are linked to the mitogen-activated protein kinase pathway resulting in 
rapid non nuclear effect such as short-term vasodilation of coronary arteries (143). 
There is also evidence suggesting across-talk between different signaling pathways 
such as wnt and ras influenced by estrogen (125). In the uterine tissue, estradiol 
increased the expression of wnt4 protein thereby activating the canonical wnt 
signaling pathway and promoted growth via modulation of downstream regulatory 
genes of ~3-catenin such as cyclin-D, c-myc, c-fos and COX-2 in an ER-independent 
pathway (124). Differential expression of COX-2 via the wnt signaling pathway has 
also been reported in colon epithelial cells that differ in APC (123). These reports 
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suggest a complex interplay of different signaling pathways that estrogen might 
possibly influence in modulating the COX-2 protein levels. 
The metabolism of estrogens in the colon has not been well described, 
although 17~3HSD activity and aromatase/cytochrome P450 activity are present in 
colon. Peripheral synthesis of estrogen and the interconversion of estrone and 
estrodiol depending on the reducing or oxidizing activity 17RHSD also might 
influence the estrogen mediated suppressive effect of COX-2. Inactivation of 
estradiol via conversion to estrone has been suggested to have a protective effect 
while loss of this inactivation may lead to cell proliferation via an ER-dependent 
pathway (59). Our study does not specifically address this question but suggested 
a protective effect of estrone via suppression of COX-2. 
Thus, many questions remain to be answered including the role of estrogen 
receptors in mediating the effect of phytoestrogens on colon cells, the role of 
estrogen receptors and estrogen metabolizing enzymes in the colon, changes in 
estrogen receptor expression and/or responsiveness during the carcinogenic 
process and the overall role of dietary factors on estrogen receptors and estrogen 
related pathway in colon. 
We also attempted to investigate the correlation of ACF and mucin depleted 
foci (MDF) with dietary factors. Our rationale to do MDF along with ACF was for the 
following reasons. 
1. Numerous studies have used ACF as a short-term marker for predicting colon 
carcinogenesis especially for chemopreventive compounds (34, 35). 
However, conflicting results on the association between ACF and tumor 
development have been reported (86, 87). Zheng et al (86) reported a higher 
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tumor incidence in rats administered 2-carboxyphenyl retinamide (2-CPR) 
compared to controls, but reduced ACF incidence previously. Moreover, rats 
fed cholic acid had fewer ACF but more tumors than rats fed a control diet 
which suggest ACF may not correlate with tumor incidence (86, 87). Also, the 
incidence of ACF in genetically susceptible strains and resistant strains of 
mice were similar but differed in tumor incidence suggested a lack of 
correlation of number of ACF with tumorigenesis (88). These results 
suggested that ACF may be a preliminary biomarker but other events are 
involved in advancing ACF to adenoma or adenocarcinoma. 
2. It has been suggested that ACF with mucin depletion and R-catenin 
accumulation along with other genetic alterations correlated to progression of 
ACF to adenoma-carcinoma (133, 144, 145). Mucin depletion of ACF has 
also been observed in human colon cancer specimens (133). Figure 4.1 
presented from reference (133) depicts the significance of ACF with MDF 
(1.3% of ACF) and ~3- catenin accumulated crypts with their correlation to 
tumorigenesis. 
Thus, in order to have a better preneoplastic marker and to investigate the role of 
estrogen and genistein in modulating ACF and MDF and their correlation, we 
attempted to quantify both ACF and MDF. However, we faced difficulty in clearly 
distinguishing the MDF. One possible reason for our inability to identify MDF could 
be due to the low percent of ACF with mucin depletion in our samples. Considering 
the incidence of ACF in our study, 5-8 per colon the probability of detecting MDF 
was very low (~1 %) (133). Other factors such as the short duration of the study, and 
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the potential effect of diet and estrogenic compounds also might have influenced the 
outcome. 
Our observation of no effect of dietary estrogens on ACF does not agree with 
other studies studying the effect of soy and soy isoflavones on ACF (34, 37). The 
use of different chemicals in inducing ACF such as AOM or dimethylhydrazine 
(DMH), the time of exposure to the carcinogen, species differences, as well as 
dietary regimens before or after carcinogen exposure might have influenced these 
Figure 4.1 Aberrant crypt foci, Mucin depleted foci and ~3-catenin accumulated crypts 
8.0% 
 ~ Normal looking crypts (NLC) 
85.1 
Histological ACF (hyperplastic) 
6.9% 
DF (dysplastic) ACF 
7.6% 
0 100% 75 /o 
 DF (dysplastic) ACF  ' 
93% 
76.4% 
  DF Dysplastic type of ACF 
Normal looking crypts (NLC) 
R-
catenin 
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(BCAC) 
Source: Modified from Yamada and Mori. Cancer Sci. 2004 Oct;95(10):792-7. 
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results. However, it is not clear if ACF are true markers of tumor development and 
the lack of response of ACF in the Soy+E1 fed mice would suggest that at least in 
the AOM-treated C57BL/J6 mouse they are not predictive of tumor development. 
Mice fed the experimental diets gained weight similarly throughout the study 
(Figure 3.2). However, slight differences in body weight due to diet were observed 
at termination (Vable 3.1). The differences in body weight occurred during the last 2 
weeks of the study (Figure 3.2.). Mice fed Soy-IF weighed slightly more than mice 
fed Soy+Gen. Mice fed Soy-IF had more abdominal fat than mice fed Soy+Gen 
which may partially explain the differences in body weight. We expressed organ 
weights as a percent of body weight to correct for differences in animal size. We 
observed that organ weights including colon, cecum, spleen and kidney of mice fed 
Soy-IF diets were significantly lower than from mice fed Soy+E1 (P<_ 0.005) (Table 
3.1). The reason for this is not known 
The primary therapy for patients with HNPCC and FAP has been COX 
inhibition. COX-2 expression is rapidly induced by growth factors, oncogenes, and 
tumor promoters. Previous research has shown elevated levels of eicosanoids, 
particularly PGE2 during initiation and post initiation stages generated by COX-2 
activity as well as the COX-2 activity increases with more advances of tumor (98, 
106, 146). COX-2 is the rate limiting step in the generation of prostaglandins 
including PGE2 and PGF2a that may mediate cellular proliferation via the wnt or 
Ras signaling pathways (125). Also, it is been suggested that COX-2 generated 
prostaglandins mediate various physiological effects including apoptosis, immune 
modulation, and angiogenesis as well as modulation of second messenger signaling 
pathways such as elevation of intracellular cyclic AMP(102). Thus, our observation 
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of soy protein with estrone and soy protein with genistein in suppression of COX-2 is 
of potential significance. There is also a need to investigate the complex molecular 
mechanisms that are involved in the tissue specific regulation of the COX-gene by 
estrogenic compounds in the colon. 
This observation is helpful in the use of plant-derived phytochemicals as 
chemopreventive agents which circumvent the various side effects associated with 
COX inhibition by NSAIDs as well as COX-2 specific inhibitors. However, genistein 
may not be completely without negative side effects. There is evidence for 
reproductive, genetic, thyroid and developmental toxicity from animal studies of 
genistein exposure (147, 148). There is also controversy with the exposure of 
genistein in infants fed soy formula and their physiological effects on the immune 
system as well (148). Thus, research in this area is still in its nascent stage in 
determining their overall affect as well as in colon carcinogenesis. 
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Table 5.1 Inter and intra-gel coefficient variances (CV) of western blotting 
Inter-g e I C ®X-2 
Mean 0.37 
SD 0.05 
CV% 13.78 
n=8 
Intra-gel 
Mean 6.54 
SD 0.12 
CV% 1.89 
n=4 
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Example experiment data sheet 
Experiment # Date 
TITLE: 
Western Blot Analysis of COX-2 expression in Casein, Soy-IF, Soy+Gen, Soy+E1 
fed ovariectomized C57BL/J6 mice 
PURPOSE: 
In this experiment, COX-2 protein levels will be examined in mice colon that were 
fed 4 diet groups viz. Casein, Soy-IF, Soy+Gen, Soy+E1 after 6weeks of last dose of 
6 weeks of AOM (10mg/kg of body weight). The colon cells were scraped using a 
microscope slide and collected in a lysis buffer (150mM NaCI, 50mM hepes with 1% 
protease inhibitors) that were flash frozen in liquid nitrogen and ultrasonicated for 
3X15 secs, 15 secs apart and spun at 120,000 g called the supernatant(SN) and 
stored in -80°C at Food sciences building 
The tubes used were the 100u1 aliquots from the samples spun on Oct 17, 05 
From the earlier results that indicated thicker, stronger bands at 1 min exposure of 
film and 5 min exposure we decided to go for lesser concentration of the protein. 
10/21 /05: Quantified the protein by BCA protein assay kit. 
1. Block 1.5% BSA and 1.5% milk in TBS 
2. Detection system: West Femto super sensitivity substrate 
3. Santa-Cruz 1 °antibody (1:10,000) —overnight incubation 
4. 2° antibody mouse (goat anti-mouse HRP conjugated) at 1:50,000 for anti-
cox-2 and 1:5000 for b-tubulin 
5. COX-2 standard (1 ul (0.47mg/ml) diluted in 1400u1 of 1 X loading buffer) 
METHODS: 
The Western protocol is using 0.1% SDS in the running buffer and using 10% 
minigels made as follows: 
FOR 2 MINIGELS (1.5mm thick) 10% resolving 4% stacking 
30% Acrylamide/0.8% Bisacrylamide 6ml 0.67 ml 
1.5M Tris, pH 8.8 0.5M Tris pH 6.8 5 ml 1.25 ml 
dH2O 8.10 ml 3.07 ml 
10% S®S 200u1 50 ul 
TEMED (Biorad #161-0800) 20u1 5 ul 
APS (10%) 100u1 25 ul 
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MATERIALS: 
Cat. # Lot # Dilutions Comments 
Mol. Wt 161- Kaleidoscope prestained 
marker 0324 standards control — 99462 — Bio-
Rad 
Cox-2 std C-0858 Human, recombinant expressed 
in Sf21 cells, Sigma 
1°Cox-2 Sc- H2504 1:10,000 Mouse monoclonal IgG 200ug/ml 
19999 —Santa Cruz 
2° Sc- B2505 1:50,000 Goat anti-mouse igG-HRP —
2005 Santa Cruz 
❑-tubulin SC- 1:10,000 Santa Cruz biotechnology inc. 
5274 Mol. Wt 55kDa 
West 
femto 
substrate 
34094 1:1 Pierce-super signal west femto 
maximum sensitivity substrate 
Gel PBCOX-2 Expt #Date 
No. Mouse # -diet 
(cage#, diet 
group, Mouse 
era hole) 
Amount 
of 
protein 
ug 
Volume 
of 
sample / 
well ul 
6X SB 1XSB Total 
volume/ 
well - ul 
1 Blank 30 30 
2 1 CN- Casein 5 11.5 2.3 16.2 30 
3 31N-Soy-IF 5 10.4 2.1 17.5 30 
4 5GL-Soy+Gen 5 11.7 2.3 15.9 30 
5 8EL- Soy+E1 5 9.8 2 18.3 30 
6 cox-2 std 
(0.336ng/ul) 
10ng 30 
7 Mol.wt std 10 
8 2CB -casein 5 13.3 2.7 14.1 30 
9 41B —Soy-IF 5 13.1 2.6 14.2 30 
10 6GL Soy+gen 5 12.0 2.4 15.7 30 
11 9EB Soy+E1 5 9.8 2.0 18.3 30 
12 Blank 30 
13 31R- repeat ctrl 5 7.8 1.6 20.6 30 
14 Mol. Wt std 10 
15 Blank 
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Gel PBCOX-2 Expt #Date 
No. Mouse # -diet 
(cage#, diet 
group, Mouse 
era hole) 
Amount 
of 
protein 
ug 
Volume 
of 
sample / 
well ul 
6X SB 1XSB Total 
volume/ 
well - ul 
1 Blank 30 30 
2 Mol. wt std 10 
3 2CN- Casein 5 11.2 2.2 16.5 30 
4 41 N-Soy-I F 5 13.8 2.8 13.4 30 
5 6GN-Soy+Gen 5 9.5 1.9 18.6 30 
6 10EN-Soy+E1 5 10.8 2.2 17.1 30 
7 COX-2 STD 10ng 30 
8 2CR -casein 5 8.4 1.7 19.9 30 
9 41R —Soy-IF 5 11.4 2.3 16.3 30 
10 6GR Soy+gen 5 10.0 2.0 18.0 30 
11 8EN Soy+E1 5 14.0 2.8 13.2 30 
12 Blank 30 30 
13 31R-repeat ctrl 5 7.8 1.6 20.6 30 
14 M o I . wt std 10 
15 Blank 30 
Experiment Data Sheet 
Cox-2 Western Experiment #PBCox-2-03 
Ames: 
Gels Gels 1 Gel 2 
Date of Run 
Resolving gel polymerizn 
Stacking gel polymerizn 
Load samples 
Run time: const volts 200 
v o l t:~ ~ 1 h r 
Start/end current of run 
Gel: in transfer buffer 
Transfer time: const voltage 
100if 
Start/end current of transfer 
Block in 1.5 %milk &1.5% 
Bsa 
